Pande, Amitkumar <br/><br/>
Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.  [electronic resource] 

 -  Anticancer research   
 - 3465-70 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0250-7005 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--adverse effects<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Bevacizumab<br/>Female<br/>Humans<br/>Hypertension--chemically induced<br/>Incidence<br/>Male<br/>Middle Aged<br/>Neovascularization, Pathologic--drug therapy<br/>Protein Kinase Inhibitors--pharmacology<br/>United States--epidemiology<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor Receptor-1--metabolism<br/>Vascular Endothelial Growth Factor Receptor-2--metabolism